SRRK

+ Watchlist + Portfolio

Scholar Rock Holding Corp.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $46.16
52-Week Range: $27.07 – $61.76
Market Cap: $5.70B
P/E (TTM): —
EPS (TTM): -3.32
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 22.43
PEG Ratio: —
Return on Equity: -167.77%
Return on Assets: -58.82%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 7.02
Debt/Equity: 0.80
Total Debt: $203.83M
Free Cash Flow: $-153.88M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $5.41B

SRRK Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$33.19M	$0.00	$0.00	$0.00
Research & Development	$124.44M	$121.90M	$184.55M	$208.44M
Selling, General & Admin	$43.12M	$49.40M	$67.50M	$176.21M
Operating Expenses	$167.56M	$171.29M	$252.05M	$384.64M
Operating Income	-$134.37M	-$171.29M	-$252.05M	-$384.64M
EBITDA	-$131.38M	-$168.45M	-$237.52M	-$369.39M
Pretax Income	-$134.50M	-$165.79M	-$246.29M	-$377.94M
Net Income	-$134.50M	-$165.79M	-$246.29M	-$377.94M
Diluted EPS	-2.26	-1.99	-2.47	-3.29
Diluted Shares	59.61M	83.35M	99.84M	114.70M

SRRK Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$103.28M	$101.86M	$177.88M	$323.53M
Receivables	$2.73M	$1.08M	$2.15M	$2.80M
Current Assets	$328.02M	$288.19M	$451.17M	$385.15M
Total Assets	$358.17M	$311.04M	$474.92M	$404.27M
Current Liabilities	$36.39M	$32.74M	$46.94M	$55.42M
Long-Term Debt	$49.74M	$48.68M	$50.15M	$99.71M
Total Debt	$69.40M	$61.82M	$65.13M	$108.92M
Total Liabilities	$97.93M	$85.82M	$106.29M	$158.78M
Retained Earnings	-$510.63M	-$676.42M	-$922.72M	-$1.30B
Shareholders' Equity	$260.24M	$225.22M	$368.63M	$245.49M
Working Capital	$291.63M	$255.45M	$404.23M	$329.73M

SRRK Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$132.69M	-$145.23M	-$200.95M	-$300.04M
Capital Expenditure	-$1.06M	-$71.00K	-$98.00K	-$602.00K
Free Cash Flow	-$133.76M	-$145.30M	-$201.05M	-$300.64M
Depreciation & Amortisation	$2.99M	$2.84M	$1.94M	$1.66M
Stock-Based Compensation	$27.70M	$27.14M	$36.63M	$75.60M
Investing Cash Flow	-$171.70M	$41.14M	-$76.06M	$218.69M
Financing Cash Flow	$194.83M	$102.57M	$353.03M	$228.40M
Net Change in Cash	-$109.56M	-$1.51M	$76.02M	$147.05M

SRRK Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$48.68M	$62.40M	$50.49M	$46.88M	$51.81M	$58.23M
Selling, General & Admin	$28.41M	$49.71M	$53.06M	$45.02M	$50.20M	$50.67M
Operating Expenses	$77.09M	$112.11M	$103.55M	$91.90M	$102.02M	$108.90M
Operating Income	-$77.09M	-$112.11M	-$103.55M	-$91.90M	-$102.02M	-$108.90M
EBITDA	-$72.51M	-$108.41M	-$100.46M	-$88.01M	-$102.87M	-$105.08M
Pretax Income	-$74.72M	-$110.03M	-$102.22M	-$90.97M	-$105.51M	-$109.90M
Net Income	-$74.72M	-$110.03M	-$102.22M	-$90.97M	-$105.51M	-$109.90M
Diluted EPS	-0.67	-0.98	-0.90	-0.88	-0.83	-0.84
Diluted Shares	111.84M	112.70M	113.73M	103.09M	127.28M	130.61M

SRRK Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$137.93M	$152.93M	$286.77M	$323.53M	$430.54M	$437.09M
Receivables	$1.94M	$1.97M	$3.55M	$2.80M	$21.48M	$1.96M
Current Assets	$385.25M	$319.13M	$390.71M	$385.15M	$515.28M	$507.18M
Total Assets	$407.55M	$340.05M	$411.72M	$404.27M	$535.25M	$523.54M
Current Liabilities	$37.57M	$50.44M	$61.97M	$55.42M	$59.64M	$72.24M
Long-Term Debt	$49.74M	$49.76M	$99.61M	$99.71M	$196.61M	$196.20M
Total Debt	$63.14M	$61.53M	$110.08M	$108.92M	$205.67M	$203.83M
Total Liabilities	$95.22M	$106.75M	$166.72M	$158.78M	$259.24M	$269.76M
Retained Earnings	-$997.44M	-$1.11B	-$1.21B	-$1.30B	-$1.41B	-$1.52B
Shareholders' Equity	$312.33M	$233.29M	$245.00M	$245.49M	$276.01M	$253.78M
Working Capital	$347.67M	$268.69M	$328.74M	$329.73M	$455.64M	$434.94M

SRRK Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$78.67M	-$76.94M	-$68.92M	-$75.50M	-$82.10M	-$70.31M
Capital Expenditure	-$271.00K	-$215.00K	-$84.00K	-$32.00K	-$68.00K	-$1.00K
Free Cash Flow	-$78.95M	-$77.16M	-$69.01M	-$75.53M	-$82.17M	-$70.31M
Depreciation & Amortisation	$393.00K	$417.00K	$423.00K	$425.00K	$335.00K	$297.00K
Stock-Based Compensation	$13.41M	$24.43M	$18.33M	$19.42M	$18.25M	$19.66M
Investing Cash Flow	$34.55M	$85.47M	$59.70M	$38.97M	-$5.33M	-$5.50M
Financing Cash Flow	$4.17M	$6.47M	$144.47M	$73.29M	$193.79M	$83.12M
Net Change in Cash	-$39.95M	$15.00M	$135.25M	$36.76M	$106.35M	$7.31M

Market Snapshot

About

Scholar Rock Holding Corp. is a biopharmaceutical company focused on developing innovative therapies for serious diseases. The company specializes in targeting growth factor signaling pathways, with lead programs in spinal muscular atrophy, obesity, and cancer. Its proprietary platform enables the discovery of monoclonal antibodies that modulate growth factor activity.